Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Roy T. Steigbigel, M.D., David A. Cooper, M.D., D.Sc., Princy N. Kumar, M.D., Joseph E. Eron, M.D.,
Mauro Schechter, M.D., Ph.D., Martin Markowitz, M.D., Mona R. Loutfy, M.D., M.P.H., Jeffrey L. Lennox, M.D.,
Jose M. Gatell, M.D., Ph.D., Jurgen K. Rockstroh, M.D., Christine Katlama, M.D., Patrick Yeni, M.D.,
Adriano Lazzarin, M.D., Bonaventura Clotet, M.D., Jing Zhao, Ph.D., Joshua Chen, Ph.D., Desmond M. Ryan, B.S.,
Rand R. Rhodes, M.S., John A. Killar, M.S., Lucinda R. Gilde, B.S., Kim M. Strohmaier, B.S., Anne R. Meibohm, Ph.D.,
Michael D. Miller, Ph.D., Daria J. Hazuda, Ph.D., Michael L. Nessly, M.S., Mark J. DiNubile, M.D., Robin D. Isaacs, M.D.,
Bach-Yen Nguyen, M.D., and Hedy Teppler, M.D., for the BENCHMRK Study Teams*

ABSTRACT

BACKGROUND

Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs.

METHODS

We conducted two identical trials in different geographic regions to evaluate the safety and efficacy of raltegravir, as compared with placebo, in combination with optimized background therapy, in patients infected with HIV-1 that has triple-class drug resistance in whom antiretroviral therapy had failed. Patients were randomly assigned to raltegravir or placebo in a 2:1 ratio.

RESULTS

In the combined studies, 699 of 703 randomized patients (462 and 237 in the raltegravir and placebo groups, respectively) received the study drug. Seventeen of the 699 patients (2.4%) discontinued the study before week 16. Discontinuation was related to the study treatment in 13 of these 17 patients: 7 of the 462 raltegravir recipients (1.5%) and 6 of the 237 placebo recipients (2.5%). The results of the two studies were consistent. At week 16, counting noncompletion as treatment failure, 355 of 458 raltegravir recipients (77.5%) had HIV-1 RNA levels below 400 copies per milliliter, as compared with 99 of 236 placebo recipients (41.9%, P<0.001). Suppression of HIV-1 RNA to a level below 50 copies per milliliter was achieved at week 16 in 61.8% of the raltegravir recipients, as compared with 34.7% of placebo recipients, and at week 48 in 62.1% as compared with 32.9% (P<0.001 for both comparisons). Without adjustment for the length of follow-up, cancers were detected in 3.5% of raltegravir recipients and in 1.7% of placebo recipients. The overall frequencies of drug-related adverse events were similar in the raltegravir and placebo groups.

CONCLUSIONS

In HIV-infected patients with limited treatment options, raltegravir plus optimized background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks. (ClinicalTrials.gov numbers, NCT00293267 and NCT00293254.)

From the State University of New York at Stony Brook, Stony Brook (R.T.S.); National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney (D.A.C.); Georgetown University Medical Center, Washington, DC (P.N.K.); University of North Carolina, Chapel Hill (J.E.E.); Universidade Federal do Rio de Janeiro, Rio de Janeiro (M.S.); Aaron Diamond Research Center, Rockefeller University, New York (M.M.); University of Toronto, Toronto (M.R.L.); Emory University School of Medicine, Atlanta (J.L.L.); University of Barcelona, Barcelona (J.M.G.); University of Bonn, Bonn, Germany (J.K.R.); Hospital Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris (C.K.); Hospital Bichat-Claude Bernard, Paris (P.Y.); San Raffaele Scientific Institute, Milan (A.L.); Hospital Germans Trias i Pujol, Fundación Irsicaixa, Barcelona (B.C.); and Merck Research Laboratories, North Wales, PA (J.Z., J.C., D.M.R., R.R.R., J.A.K., L.R.G., K.M.S., A.R.M., M.D.M., D.J.H., M.L.N., M.J.D., R.D.I., B.-Y.N., H.T.). Address reprint requests to Dr. Teppler at Merck Research Laboratories, P.O. Box 1000, UG3D-56, North Wales, PA 19454-1099, or at hedy_ teppler@merck.com.

*The members of the BENCHMRK (Blocking Integrase in Treatment Experienced Patients with a Novel Compound against HIV, Merck) study teams are listed in Supplementary Appendix 1, available with the full text of this article at www. nejm.org.

N Engl J Med 2008;359:339-54.

IGHLY ACTIVE ANTIRETROVIRAL THERapy is the standard of care for patients with advanced human immunodeficiencv virus (HIV) infection.1 Combination regimens have resulted in improved survival, decreased morbidity, and cost-effective care for patients with a CD4 count of less than 350 per cubic millimeter.2-8 However, viral suppression cannot always be achieved or sustained with standard treatments because of the development of viral resistance, toxic effects of drugs, or lack of adherence.9-18 The majority of HIV-infected patients in whom highly active antiretroviral therapy fails have resistant viral quasispecies.12-15,19,20 Crossresistance to agents within a drug class may exhaust most available treatment options.1,21 Antiretroviral drugs directed at new HIV targets are urgently needed for patients with unsuppressed viremia despite treatment.14,22-24

Integrase is a viral enzyme that is essential for HIV type 1 (HIV-1) replication, catalyzing the insertion of proviral DNA into the host-cell genome.²⁵ Because HIV-1 integrase represents a distinct therapeutic target, integrase inhibitors would be expected to maintain activity against HIV-1 strains even when resistant to other classes of antiretroviral drugs.²⁶⁻²⁸ Raltegravir (MK-0518; Isentress, Merck) specifically inhibits proviral DNA-strand transfer, with potent in vitro activity against HIV-1 that is susceptible or resistant to other classes of antiretroviral drugs.27,29,30 In combination with optimized background therapy in a placebo-controlled, dose-ranging phase 2 study involving patients with resistant infection, raltegravir given at a dose of 200 mg, 400 mg, or 600 mg twice daily suppressed plasma HIV-1 RNA to a level below 50 copies per milliliter at week 24 in 56 to 67% of recipients across the dose groups, as compared with 13% of patients receiving optimized background therapy alone.³¹ Because the three doses tested in the phase 2 program were similarly efficacious and had acceptable side-effect profiles, the middle dose of 400 mg twice daily was chosen for further study, providing a margin of safety and efficacy when raltegravir is coadministered with drugs that are inhibitors or inducers of its major metabolizing enzyme (uridine diphosphate glucuronosyltransferase isoform 1A1).29 In this report, we present clinical trial data on the safety, adverse-effect profile, and virologic and immunologic effects of combining raltegravir (400 mg twice daily)

with optimized background therapy in HIV-infected adults with unsuppressed viremia despite antiretroviral therapy.

METHODS

The studies were designed, managed, and analyzed by the sponsor in conjunction with the academic authors. The authors had access to all study data on request. This report was principally drafted by two academic authors and four industry authors and was critically reviewed and approved by all the authors in its final form before submission. All authors vouch for the completeness and accuracy of the data.

STUDY DESIGN

There are two ongoing BENCHMRK (Blocking Integrase in Treatment Experienced Patients with a Novel Compound against HIV, Merck) studies. BENCHMRK-1 (MK-0518 protocol 018, Merck) is a double-blind (including blinding of the sponsor), randomized, phase 3 clinical trial being conducted in Europe, Asia, Australia, and Peru. BENCHMRK-2 (MK-0518 protocol 019, Merck) in North and South America is identical in design to the concurrent BENCHMRK-1 trial. The protocol was approved by the institutional review board or ethics review committee at each site. All participants provided written informed consent. The planned total duration of each study is at least 156 weeks of the study therapy. This report presents efficacy results through week 48 and all available safety data from the groups through August 3, 2007, for BENCHMRK-1 and July 31, 2007, for BENCHMRK-2 (the dates when the last patient remaining in the double-blind phase of the study completed the 48-week visit).

PATIENTS

HIV-infected patients 16 years of age or older were eligible if they had HIV-1 RNA levels of more than 1000 copies per milliliter while receiving antiretroviral therapy, with documented phenotypic or genotypic resistance to at least one drug in each of three classes of oral antiretroviral drugs (nucleoside reverse-transcriptase inhibiitors, non–nucleoside reverse-transcriptase inhibitors, and protease inhibitors). Exclusion criteria were renal insufficiency (a serum creatinine level greater than twice the upper limit of the normal range), acute or decompensated chronic hepatitis, uncontrolled substance abuse, and any medical condition likely to interfere with the execution or interpretation of the study. Pregnant or breast-feeding women were also excluded. Patients with stable chronic hepatitis B or hepatitis C were eligible if their serum aminotransferase levels were less than five times the upper limit of the normal range. Patients with active cancer could be enrolled if chemotherapy was not required and the cancer was not considered likely to obscure the study outcome.

STUDY TREATMENT

At entry, investigators selected optimized background therapy for each patient on the basis of the history of antiretroviral treatment, results of available drug-resistance tests, and previous or current laboratory data. Darunavir and tipranavir, which were investigational at the time of the studies, were permitted as part of optimized background therapy, subject to local regulatory approval, to ensure the most active regimen for patients. The study drug and optimized background therapy were initiated concurrently. Subsequent changes to optimized background therapy were permitted only for management of toxic effects or if patients switched to open-label raltegravir because of virologic failure after week 16.

Patients were randomly assigned to raltegravir or placebo in addition to their optimized background therapy, in a 2:1 ratio, through a central, interactive voice-response system, according to a computer-generated, randomized allocation schedule. Randomization was stratified according to both the use or nonuse of enfuvirtide in the optimized background therapy and the degree of viral resistance to protease inhibitors (resistance to 1 vs. >1). Investigators, study site and sponsor personnel, patients, and laboratory personnel remained unaware of the treatment assignments and dose, with blinding accomplished through the use of placebo tablets that were identical in appearance to the raltegravir tablets. Participants were instructed to take one 400-mg tablet of raltegravir or placebo twice daily, 12 hours (±2 hours) apart, without regard to food intake.

ASSESSMENTS

Clinical status was assessed at regularly scheduled visits and as needed; protocol-mandated laboratory tests were performed in a central laboratory. HIV-1 RNA levels were measured with the standard polymerase-chain-reaction (PCR) assay (Cobas Amplicor HIV-1 Monitor assay, version 1.5; Roche Diagnostics), with lower and upper limits of quantification of 400 and 750,000 copies per milliliter, respectively. All samples for which the RNA levels were below the lower limit were evaluated with the use of a more sensitive PCR assay (Ultrasensitive Amplicor HIV-1 Monitor assay, version 1.5; Roche Diagnostics), with a lower quantification limit of 50 copies per milliliter. Resistance testing (PhenoSense GT, Monogram Biosciences), was mandated at baseline and at the time of virologic failure.

SENSITIVITY SCORES

Genotypic and phenotypic sensitivity scores for the optimized background therapy were determined from the results of baseline resistance tests. The genotypic and phenotypic sensitivity scores were the total number of antiretroviral drugs used as part of the optimized background therapy to which a patient's HIV was fully susceptible, as determined with the use of genotypic and phenotypic resistance testing, respectively. For the calculation of genotypic sensitivity scores, the drug-susceptibility results were interpreted on the basis of the Monogram algorithm available at the time. For the calculation of phenotypic sensitivity scores from the PhenoSense GT results, only antiretroviral drugs in the optimized background therapy that were active at concentrations below the cutoff point established for the fully active drug were considered to be active. A score of 0 does not rule out reduced but clinically meaningful antiretroviral activity for drugs included in the optimized background therapy. Because resistance criteria for darunavir and enfuvirtide were not available from the PhenoSense GT analysis during the study, each of the two drugs was counted (+1) in both phenotypic and genotypic sensitivity scores when used as part of the optimized background therapy in patients who had not previously been given that agent. Low-dose ritonavir (<600 mg per day) was not counted as a separate drug.

VIROLOGIC FAILURE

At or after week 16, virologic failure was considered to have occurred if the patients did not have a decrease in the HIV-1 RNA level to less than 400 copies per milliliter or by more than $1 \log_{10}$

copies per milliliter from the baseline level; if they had an increase in the HIV-1 RNA level of more than 1 \log_{10} copies per milliliter from the nadir level on two consecutive measurements; or if they had two consecutive HIV-1 RNA measurements of 400 or more copies per milliliter after having had a level of less than 400 copies per milliliter. Patients with virologic failure could opt to remain in the blinded portion of the study, enter an open-label phase and receive raltegravir as part of a new regimen, or withdraw from the study.

ADJUDICATION OF EVENTS AND OVERSIGHT BY THE DATA AND SAFETY MONITORING BOARD

Events occurring during the studies that were suspected to indicate the presence of the acquired immunodeficiency syndrome (AIDS) (other than a CD4 cell count \leq 200 cells per cubic millimeter) were reviewed by an independent adjudicator with expertise in HIV medicine who was unaware of the treatment assignment.

An independent data and safety monitoring board periodically reviewed the blinded safety and efficacy results and could request unblinded data and make nonbinding recommendations regarding the completion of enrollment and continuation of the studies. As planned, the data and safety monitoring board also reviewed the unblinded results of the primary analysis after all participants remaining in the double-blind phases of the studies had completed at least 16 weeks of follow-up (at which point the median duration of follow-up was 26 weeks [range, 1 to 39] in the raltegravir groups and 21 weeks [range, 4 to 40] in the placebo groups).

STATISTICAL ANALYSIS

The prespecified primary efficacy hypothesis for each BENCHMRK study was that, when used in combination with optimized background therapy, raltegravir would have superior antiretroviral activity to that of placebo, based on the proportion of patients with HIV-1 RNA levels of less than 400 copies per milliliter after 16 weeks of study therapy. Assuming a true response rate at week 16 of 70% among raltegravir recipients and 50% among placebo recipients and anticipating a 10% rate of discontinuation for reasons not related to treatment, we estimated that a study with a planned enrollment of 230 patients in the raltegravir group and 115 patients in the placebo group would have a statistical power of 90% to show superiority of optimized background therapy with raltegravir over optimized background therapy with placebo. Additional prespecified efficacy outcomes included the proportions of patients with HIV-1 RNA levels of less than 50 copies per milliliter and the change from baseline in CD4 cell counts.

All treated patients were included in the efficacy and safety analyses. Missing virologic data were handled in three prespecified ways.³¹ The primary analysis used a treatment-related discontinuation approach that considered patients who discontinued the double-blind phase of the study owing to lack of efficacy or adverse events (or whose HIV-1 RNA level was ≥400 [or \geq 50] copies per milliliter at the time of discontinuation for reasons not related to treatment) as having treatment failure at subsequent time points. HIV-1 RNA measurements that were missing because of skipped or mistimed visits were left as missing. A second, worst-case approach considered noncompletion as treatment failure at subsequent time points. HIV-1 RNA measurements that were missing because of skipped or mistimed visits were imputed as treatment failures in the noncompletion analysis unless the values immediately before and after the missing value both indicated successful treatment, in which case the missing value was left as missing. A third, observed-failure approach considered discontinuation due to lack of efficacy as treatment failure at subsequent time points. No other missing values were imputed.

A logistic-regression model was used to compare virologic-response rates between the two treatment groups, after adjustment for covariates that might affect the likelihood of achieving HIV RNA suppression. Independent variables incorporated into the model were the HIV-1 RNA level at baseline, presence or absence of an active protease inhibitor in the optimized background therapy (as determined by phenotypic resistance testing), first use of darunavir in the optimized background therapy (vs. either use in patients previously treated with darunavir or nonuse), first use of enfuvirtide in the optimized background therapy (vs. either use in patients previously treated with enfuvirtide or nonuse), and the study drug.

Combined analyses of both BENCHMRK studies were prespecified to provide precise esti-

mates of treatment effects. For the combined analysis of the proportion of patients who had HIV-1 RNA levels of less than 400 copies per milliliter at week 16, a covariate for the BENCHMRK study and an interaction term between study drug and BENCHMRK study were included in the logistic-regression model to examine the homogeneity of the treatment effects between the two BENCHMRK studies.

Adverse events occurring during the doubleblind phase of the study or within 14 days after discontinuation of blinded therapy were tabulated until the cutoff dates for each analysis. Investigators, while unaware of treatment assignment, were to assess the relationship of each adverse event to the study therapy; adverse events were counted as drug-related if they were judged by the investigator as definitely, probably, or possibly related to any of the study drugs (including drugs used in the optimized background therapy). The severity of laboratory abnormalities was graded according to the 1992 Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity criteria for adults (http://rcc.tech-res-intl. com/tox_tables.htm). The frequencies of adverse events were not adjusted for duration of followup except for calculations of relative risk. Diagnoses of new, progressive, or recurrent cancers, regardless of histologic grade and including in situ anal carcinoma and nonmelanoma skin cancer, were tallied as cancers. Incidence, relative risk, and time to diagnosis of cancer were based solely on the first cancer diagnosed during the double-blind phase.

All statistical tests were two-sided. P values of less than 0.05 were considered to indicate statistical significance, except for the interaction between study drug and BENCHMRK study, for which P values of less than 0.10 were considered to indicate statistical significance.

RESULTS

ENROLLMENT, FOLLOW-UP, AND BASELINE CHARACTERISTICS OF PATIENTS

Figure 1 in Supplementary Appendix 2 (available with the full text of this article at www.nejm.org) summarizes the enrollment and follow-up of patients until the cutoff dates of August 3, 2007, for BENCHMRK-1 and July 31, 2007, for BENCHMRK-2. Because discontinuations for virologic failure and entry into the open-label phase occurred more

frequently among placebo recipients than among raltegravir recipients, the median duration of follow-up for the safety analysis during the double-blind phase was 57.4 weeks (range, 3.0 to 72.0) in the raltegravir groups and 37.6 weeks (range, 5.6 to 72.9) in the placebo groups for the combined BENCHMRK studies.

Baseline characteristics were generally balanced between the two treatment groups within each BENCHMRK study (Table 1). The majority of enrolled patients were heavily pretreated white men with AIDS. Overall, 12.0% of participants were women and 32.2% of participants were nonwhite. Before enrollment, 46.2% and 7.3% of patients had received enfuvirtide and darunavir, respectively. At entry, 16.2% of patients had chronic hepatitis B or hepatitis C coinfection and 20.0% had a history of cancer or a premalignant condition.

VIROLOGIC AND IMMUNOLOGIC RESPONSES

Since few patients discontinued either BENCH-MRK study prematurely, the results of the three statistical approaches for handling missing data were similar (Table 2). The treatment effect was consistent between the two BENCHMRK studies (P>0.10 for homogeneity with each approach). On the basis of the primary, prespecified analysis counting treatment-related discontinuation as failure, HIV-1 RNA levels below 400 copies per milliliter at the primary (week 16) time point were achieved in 178 of 227 raltegravir recipients (78.4%) as compared with 48 of 117 placebo recipients (41.0%) in BENCHMRK-1 (P<0.001) and in 177 of 226 raltegravir recipients (78.3%) as compared with 51 of 118 placebo recipients (43.2%) in BENCHMRK-2 (P<0.001). According to the more stringent analysis counting any noncompletion as treatment failure, HIV RNA levels were reduced to less than 400 copies per milliliter at week 16 in 355 of 458 raltegravir recipients (77.5%) as compared with 99 of 236 placebo recipients (41.9%) (P<0.001 for each study individually and the combined studies) (Fig. 1). HIV-1 RNA was suppressed to a level of less than 50 copies per milliliter at 16 weeks in 61.8% of the raltegravir group as compared with 34.7% of the placebo group (P<0.001 for each study individually and the combined studies).

In the combined analysis considering noncompletion as failure at week 48, HIV-1 RNA levels were reduced to less than 400 copies per

Sex — no. (%) Male Female Race or ethnic group — no. (%)† White Black Asian Hispanic Other	Raltegravir Group (N = 232) 195 (84.1) 37 (15.9) 174 (75.0)	Placebo Group (N = 118) 103 (87.3) 15 (12.7)	Raltegravir Group (N=230)	Placebo Group (N=119)	Raltegravir	Placebo Groups
Male Female Race or ethnic group — no. (%)† White Black Asian Hispanic Other	37 (15.9)			. ,	Groups (N=462)	(N=237)
Female Race or ethnic group — no. (%)† White Black Asian Hispanic Other	37 (15.9)		210 (01 2)	107 (80.0)		210 (00 ()
Race or ethnic group — no. (%)† White Black Asian Hispanic Other		15 (12 /)	210 (91.3)	107 (89.9)	405 (87.7)	210 (88.6)
White Black Asian Hispanic Other	174 (75 0)	()	20 (8.7)	12 (10.1)	57 (12.3)	27 (11.4)
Black Asian Hispanic Other	1/4//50	a.c. (03. 1)	206 (5 (0)			
Asian Hispanic Other	. ,	96 (81.4)	126 (54.8)	77 (64.7)	300 (64.9)	173 (73.0)
Hispanic Other	18 (7.8)	5 (4.2)	48 (20.9)	21 (17.6)	66 (14.3)	26 (11.0)
Other	14 (6.0)	5 (4.2)	2 (0.9)	1 (0.8)	16 (3.5)	6 (2.5)
	6 (2.6)	1 (0.8)	47 (20.4)	18 (15.1)	53 (11.5)	19 (8.0)
$\mathbf{D}_{\mathbf{r}} = \frac{1}{2} \mathbf{r}_{\mathbf{r}} \mathbf{r}} \mathbf{r}_{\mathbf{r}} $	20 (8.6)	11 (9.3)	7 (3.0)	2 (1.7)	27 (5.8)	13 (5.5)
Region — no. (%)						
North America	0	0	192 (83.5)	99 (83.2)	192 (41.6)	99 (41.8)
South America	23 (9.9)	11 (9.3)	38 (16.5)	20 (16.8)	61 (13.2)	31 (13.1)
Asia or Australia	38 (16.4)	20 (16.9)	0	0	38 (8.2)	20 (8.4)
Europe	171 (73.7)	87 (73.7)	0	0	171 (37.0)	87 (36.7)
Age — yr						
Mean	46±9	44±8	45±9	47±8	46±9	45±8
Median	46	43	45	47	45	45
Range	16–74	19–64	16–67	17–70	16–74	17–70
CD4 cell count — per mm³						
Mean	156±139	153±152	146±143	163±149	151±141	158±150
Median	140	105	102	132	119	123
Range	1–792	3–759	1–757	0–674	1–792	0–759
Plasma HIV-1 RNA level — log ₁₀ copies	s/ml‡					
Mean	4.6±0.8	4.5±0.8	4.7±0.8	4.7±0.7	4.6±0.8	4.6±0.8
Median	4.8	4.6	4.8	4.7	4.8	4.7
Range	2.6-5.9	2.3-5.9	2.3-5.9	2.3-5.9	2.3-5.9	2.3-5.9
History of AIDS — no. (%)	217 (93.5)	105 (89.0)	210 (91.3)	110 (92.4)	427 (92.4)	215 (90.7)
Previous antiretroviral therapy					()	
Years of use						
Median	11	10	10	10	10	10
Interquartile range	8–13	8–12	7–12	7–13	7–12	8–12
No. of drugs	0 10	0 12		. 10		0 12
Median	12	12	12	12	12	12
Interquartile range	9–14	9–14	9–15	9–14	9–15	9–14
Hepatitis virus coinfection — no. (%)		J 14	5 15	7 14	5 15	J 14
Neither hepatitis B nor C	183 (78.9)	91 (77.1)	202 (87.8)	110 (92.4)	385 (83.3)	201 (84.8)
Hepatitis B only	183 (78.9)	3 (2.5)		4 (3.4)	36 (7.8)	7 (3.0)
, ,			22 (9.6)			
Hepatitis C only	31 (13.4)	22 (18.6)	6 (2.6)	5 (4.2)	37 (8.0)	27 (11.4)
Hepatitis B and C	4 (1.7)	2 (1.7)	0	0	4 (0.9)	2 (0.8)
Randomization stratum — no. (%)	00 (27 5)	42 (26 1)	07 (27 0)	46 (20 7)		00 (07 5)
Enfuvirtide in OBT Resistance to >1 protease inhibitor	88 (37.9) 225 (97.0)	43 (36.4) 112 (94.9)	87 (37.8) 222 (96.5)	46 (38.7) 114 (95.8)	175 (37.9) 447 (96.8)	89 (37.6) 226 (95.4)

Table 1. (Continued.)							
Characteristic	BENCH	IMRK-1	BENCH	IMRK-2	Combined BENCHMRK Studies		
	Raltegravir Group (N=232)	Placebo Group (N=118)	Raltegravir Group (N=230)	Placebo Group (N=119)	Raltegravir Groups (N=462)	Placebo Groups (N=237)	
No. of antiretroviral drugs in OBT							
Median	4	4	4	4	4	4	
Range	1–7	2–6	2–6	2–7	1–7	2–7	
Enfuvirtide use in OBT — no. (%)							
No	144 (62.1)	75 (63.6)	143 (62.2)	73 (61.3)	287 (62.1)	148 (62.4)	
Yes, in patients who had previ- ously used enfuvirtide	40 (17.2)	19 (16.1)	43 (18.7)	22 (18.5)	83 (18.0)	41 (17.3)	
Yes, in patients who had not used enfuvirtide¶	48 (20.7)	24 (20.3)	44 (19.1)	24 (20.2)	92 (19.9)	48 (20.3)	
Darunavir use in OBT — no. (%)							
No	156 (67.2)	83 (70.3)	122 (53.0)	55 (46.2)	278 (60.2)	138 (58.2)	
Yes, in patients who had previ- ously used darunavir	14 (6.0)	5 (4.2)	4 (1.7)	4 (3.4)	18 (3.9)	9 (3.8)	
Yes, in patients who had not used darunavir§	62 (26.7)	30 (25.4)	104 (45.2)	60 (50.4)	166 (35.9)	90 (38.0)	
No. of active protease inhibitors in OBT — no. (%)∥							
0	101 (43.5)	55 (46.6)	67 (29.1)	43 (36.1)	168 (36.4)	98 (41.4)	
≥l	123 (53.0)	61 (51.7)	155 (67.4)	76 (63.9)	278 (60.2)	137 (57.8)	
Missing data	8 (3.4)	2 (1.7)	8 (3.5)	0	16 (3.5)	2 (0.8)	
Phenotypic sensitivity score — no. (%	6)**						
0	45 (19.4)	21 (17.8)	24 (10.4)	23 (19.3)	69 (14.9)	44 (18.6)	
1	67 (28.9)	39 (33.1)	78 (33.9)	33 (27.7)	145 (31.4)	72 (30.4)	
2	67 (28.9)	33 (28.0)	75 (32.6)	33 (27.7)	142 (30.7)	66 (27.8)	
≥3	44 (19.0)	21 (17.8)	41 (17.8)	27 (22.7)	85 (18.4)	48 (20.3)	
Missing data	9 (3.9)	4 (3.4)	12 (5.2)	3 (2.5)	21 (4.5)	7 (3.0)	
Genotypic sensitivity score — no. (%)**						
0	70 (30.2)	34 (28.8)	45 (19.6)	32 (26.9)	115 (24.9)	66 (27.8)	
1	76 (32.8)	48 (40.7)	102 (44.3)	48 (40.3)	178 (38.5)	96 (40.5)	
2	57 (24.6)	22 (18.6)	54 (23.5)	27 (22.7)	111 (24.0)	49 (20.7)	
≥3	26 (11.2)	13 (11.0)	25 (10.9)	10 (8.4)	51 (11.0)	23 (9.7)	
Missing data	3 (1.3)	1 (0.8)	4 (1.7)	2 (1.7)	7 (1.5)	3 (1.3)	

* Plus-minus values are means ±SD. Nominal P values for differences between the raltegravir and placebo groups in the data from the combined BENCHMRK studies were all greater than 0.05, with the exception of hepatitis virus coinfection, for which P=0.047. OBT denotes optimized background therapy.

† Race or ethnic group was self-reported.

t The dynamic range of the standard polymerase-chain-reaction assay was 400 to 750,000 copies per milliliter.

Mepatitis B infection was defined as a positive test for hepatitis B surface antigen, and hepatitis C infection was defined as a positive test for hepatitis C antibody.

For purposes of calculating the sensitivity scores, enfuvirtide use in patients who had not previously received enfuvirtide was always counted as one active drug in OBT, and darunavir use in patients who had not previously received darunavir was always counted as an active protease inhibitor in OBT.

The number of active protease inhibitors was determined by means of phenotypic resistance testing. For patients for whom there were missing results for genotypic or phenotypic resistance testing (or both), the number of active protease inhibitors in OBT was assigned a value of ≥1 when darunavir was used and the patient had not previously received darunavir.

** The phenotypic and genotypic sensitivity scores are the total number of antiretroviral drugs used as part of the optimized background therapy to which a patient's HIV was fully susceptible, as determined with the use of phenotypic and genotypic resistance testing.

Table 2. Results of Efficacy Analyses, According to the Statistical Approach Used to Handle Discontinuations and Other Missing Data.*							
Type of Analysis	Plasma HIV-1 R	NA Level <400 C	opies/ml	Plasma HIV-1 RNA Level <50 Copies/ml			
	Raltegravir Group	Placebo Group	P Value	Raltegravir Group	Placebo Group	P Value	
	no. of responders included in the			no. of responders/no. of patients included in the analysis (%)			
Wk 16, BENCHMRK-1 data							
Treatment-related discontinuation counted as failure	178/227 (78.4)	48/117 (41.0)	<0.001	141/227 (62.1)	39/117 (33.3)	<0.001	
Noncompletion counted as failure	178/229 (77.7)	48/117 (41.0)	<0.001	141/229 (61.6)	39/117 (33.3)	<0.001	
Observed lack of efficacy counted as failure	178/224 (79.5)	48/113 (42.5)	<0.001	141/224 (62.9)	39/113 (34.5)	<0.001	
Wk 16, BENCHMRK-2 data							
Treatment-related discontinuation counted as failure	177/226 (78.3)	51/118 (43.2)	<0.001	142/226 (62.8)	43/118 (36.4)	<0.001	
Noncompletion counted as failure	177/229 (77.3)	51/119 (42.9)	<0.001	142/229 (62.0)	43/119 (36.1)	<0.001	
Observed lack of efficacy counted as failure	177/222 (79.7)	51/117 (43.6)	<0.001	142/222 (64.0)	43/117 (36.8)	<0.001	
Wk 48, combined BENCHMRK data							
Treatment-related discontinuation counted as failure	332/454 (73.1)	88/235 (37.4)	<0.001	285/454 (62.8)	78/235 (33.2)	<0.001	
Noncompletion counted as failure	332/459 (72.3)	88/237 (37.1)	<0.001	285/459 (62.1)	78/237 (32.9)	<0.001	
Observed lack of efficacy counted as failure	332/443 (74.9)	88/228 (38.6)	<0.001	285/443 (64.3)	78/228 (34.2)	<0.001	

* The analysis counting treatment-related discontinuation as treatment failure was the prespecified primary approach for the efficacy analysis. P values were calculated with the use of a prespecified logistic-regression model adjusted for baseline HIV-1 RNA level, presence or absence of an active protease inhibitor in optimized background therapy (OBT) (as determined by phenotypic resistance testing), first use of darunavir in OBT (vs. either use in patients previously treated with darunavir or nonuse), first use of enfuvirtide in OBT (vs. either use in patients previously treated with enfuvirtide or nonuse), and treatment group.

milliliter in 332 of 459 raltegravir recipients (72.3%) as compared with 88 of 237 placebo recipients (37.1%) (P<0.001 for each study individually and the combined studies). In the combined analysis, HIV-1 RNA levels were suppressed to less than 50 copies per milliliter at week 48 in 285 of 459 raltegravir recipients (62.1%) as compared with 78 of 237 placebo recipients (32.9%) (P<0.001 for each study individually and the combined studies).


On the basis of the approach considering observed lack of efficacy as treatment failure, the overall mean change in \log_{10} HIV-1 RNA copies per milliliter at week 48 was –1.7 (95% confidence interval [CI], –1.8 to –1.6) in the raltegravir groups and –0.8 (95% CI, –0.9 to –0.6) in the placebo groups (P<0.001 for both studies individually and combined) (Fig. 2 in Supplementary Appendix 2). The mean change in CD4 cell counts between baseline and week 48 was 109 per cubic millimeter (95% CI, 98 to 121) in the raltegravir groups as compared with 45 per cubic millimeter (95% CI, 32 to 57) in the

placebo groups (P<0.001 for each study individually and the combined studies).

Confirmed AIDS-defining clinical events occurred by week 48 in 17 of the 462 patients (3.7%) in the raltegravir groups and 11 of the 237 patients (4.6%) in the placebo groups (Table A1 in Supplementary Appendix 2). In comparisons of the numbers of patients with AIDSdefining conditions in the raltegravir groups and the placebo groups, based on the person-years of follow-up in the double-blind phases of both studies, the relative risk of an AIDS-defining event with raltegravir was 0.59 (95% CI, 0.26 to 1.40). The median time at which an AIDS-defining event was diagnosed was 64 days (interquartile range, 52 to 110) among raltegravir recipients and 105 days (interquartile range, 19 to 118) among placebo recipients.

SAFETY, ADVERSE EVENTS, AND SIDE EFFECTS

During the double-blind phases from both BENCHMRK studies, clinical adverse events of any intensity were reported in 90.3% of patients



in the raltegravir groups and 88.2% of patients in the placebo groups and were considered to be related to any drug in the study regimen in 54.8% of patients receiving raltegravir and 55.3% of those receiving placebo; laboratory adverse events occurred in 25.5% of raltegravir recipients and 23.2% of placebo recipients and were considered to be drug-related in 14.7% and 13.5%, respectively (Table 3). Other than local reactions at the site of enfuvirtide injections, the most common drug-related clinical adverse events in both treatment groups were diarrhea, nausea, and headache. The most common drug-related laboratory adverse events were increased serum cholesterol, triglyceride, and aminotransferase levels in the raltegravir groups and increased cholesterol and creatinine levels and decreased neutrophil counts in the placebo groups. Moderate-to-severe clinical adverse events and laboratory abnormalities of grade 3 or 4 are reported in Table 4. Supplementary Appendix 2 lists all serious clinical adverse events (Table A2), clinical adverse events of any intensity or causality that occurred in 2% or more of patients in either treatment group (Table

Adverse Event	BENCHMRK-1		BENCHMRK-2		Combined BENCHMRK Studies	
	Raltegravir Group (N=232)	Placebo Group (N=118)	Raltegravir Group (N=230)	Placebo Group (N=119)	Raltegravir Groups (N=462)	Placebo Groups (N=237)
			number of pat	ients (percent)		
Clinical adverse event						
≥1 Event	211 (90.9)	100 (84.7)	206 (89.6)	109 (91.6)	417 (90.3)	209 (88.2)
Drug-related event	113 (48.7)	64 (54.2)	140 (60.9)	67 (56.3)	253 (54.8)	131 (55.3)
Serious event	46 (19.8)	21 (17.8)	36 (15.7)	24 (20.2)	82 (17.7)	45 (19.0)
Serious drug-related event	7 (3.0)	1 (0.8)	4 (1.7)	6 (5.0)	11 (2.4)	7 (3.0)
Death†	3 (1.3)	3 (2.5)	7 (3.0)	3 (2.5)	10 (2.2)	6 (2.5)
Discontinuation						
Owing to event	4 (1.7)	4 (3.4)	7 (3.0)	3 (2.5)	11 (2.4)	7 (3.0)
Owing to drug-related event	2 (0.9)	1 (0.8)	2 (0.9)	0	4 (0.9)	1 (0.4)
Owing to serious event	3 (1.3)	3 (2.5)	6 (2.6)	2 (1.7)	9 (1.9)	5 (2.1)
Owing to serious drug-related event	1 (0.4)	0	1 (0.4)	0	2 (0.4)	0
Laboratory adverse event						
≥1 Event	62 (26.7)	25 (21.2)	56 (24.3)	30 (25.2)	118 (25.5)	55 (23.2)
Drug-related event	38 (16.4)	17 (14.4)	30 (13.0)	15 (12.6)	68 (14.7)	32 (13.5)
Serious event	2 (0.9)	0	1 (0.4)	1 (0.8)	3 (0.6)	1 (0.4)
Serious drug-related event	0	0	0	0	0	0
Death	0	0	0	0	0	0
Discontinuation						
Owing to event	0	0	1 (0.4)	0	1 (0.2)	0
Owing to drug-related event	0	0	0	0	0	0
Owing to serious event	0	0	0	0	0	0
Owing to serious drug-related event	0	0	0	0	0	0

* For the combined data, there were no significant differences between the raltegravir and placebo groups for any type of clinical or laboratory adverse event listed in the table. Drug-related events were those determined by an investigator to be possibly, probably, or definitely related to use of any drug in the study regimen.

† One death in the placebo group in BENCHMRK-1 occurred 15 days after the discontinuation of study therapy, which was just outside the 14-day period specified in the protocol.

A3), and laboratory abnormalities of DAIDS grade groups had died during the double-blind phases 2, 3, or 4 (Table A4).

the 462 patients (2.2%) in the raltegravir groups and 6 of the 237 patients (2.5%) in the placebo tis; atypical mycobacterial infection, T-cell lym-

of the two studies. In the raltegravir groups, the As of the cutoff dates for this analysis, 10 of fatal adverse events were pneumonia, rectal bleeding, and septic shock; cryptococcal meningi-

Table 4. Clinical Adverse Events and Laboratory Abnormalities during Double-Blind Phases of the BENCHMRK Studies.*							
Event or Abnormality	BENCH	MRK-1	BENCHMRK-2		Combined BENCHMRK Studies		
	Raltegravir Group (N=232)	Placebo Group (N=118)	Raltegravir Group (N=230)	Placebo Group (N=119)	Raltegravir Groups (N=462)	Placebo Groups (N=237)	
Common drug-related clinical adverse event of moderate-to-severe intensity — no. (%)†							
Diarrhea	6 (2.6)	5 (4.2)	14 (6.1)	5 (4.2)	20 (4.3)	10 (4.2)	
Nausea	2 (0.9)	3 (2.5)	9 (3.9)	4 (3.4)	11 (2.4)	7 (3.0)	
Headache	5 (2.2)	3 (2.5)	7 (3.0)	0	12 (2.6)	3 (1.3)	
Fatigue	1 (0.4)	0	6 (2.6)	2 (1.7)	7 (1.5)	2 (0.8)	
Reaction at injection site	6 (2.6)	4 (3.4)	7 (3.0)	5 (4.2)	13 (2.8)	9 (3.8)	
Pain at injection site	5 (2.2)	1 (0.8)	2 (0.9)	1 (0.8)	7 (1.5)	2 (0.8)	
Laboratory abnormality of grade 3 or 4 — $\%$ ‡							
Absolute neutrophil count <750 cells/mm³	3.4	2.5	4.8	5.9	4.1	4.2	
Hemoglobin <7.5 g/dl	1.7	0.8	0.4	0	1.1	0.4	
Platelet count <50,000/mm ³	2.6	1.7	0.4	0	1.5	0.8	
Fasting LDL cholesterol ≥190 mg/dl (4.9 mmol/liter)§	7.8	6.4	2.8	1.8	5.3	4.1	
Fasting total cholesterol >300 mg/dl (7.8 mmol/liter)	11.6	4.2	4.3	5.0	8.0	4.6	
Fasting triglycerides >750 mg/dl (8.5 mmol/liter)	7.3	2.5	9.6	7.6	8.4	5.1	
Fasting glucose >250 mg/dl (13.9 mmol/liter)	1.7	1.7	1.7	1.7	1.7	1.7	
Creatinine >1.8×ULN	0	0	2.6	2.5	1.3	1.3	
Total bilirubin >2.5 × ULN	4.3	0.8	3.0	4.2	3.7	2.5	
Alkaline phosphatase >5×ULN	1.7	2.5	0.4	0.8	1.1	1.7	
Pancreatic amylase >2×ULN	3.9	2.5	4.8	2.5	4.3	2.5	
Lipase >3 × ULN	1.7	0.8	0.4	0.8	1.1	0.8	
Aspartate aminotransferase $>5 \times ULN$	3.0	3.4	3.9	5.0	3.5	4.2	
Alanine aminotransferase $>5 \times ULN$	6.5	4.2	2.2	2.5	4.3	3.4	
Creatine kinase >10×ULN	4.7	2.5	6.1	4.2	5.4	3.4	

* Nominal P values for differences between the raltegravir and placebo groups in the data from the combined BENCHMRK studies were all greater than 0.05. Table A3 in Supplementary Appendix 2 lists all clinical adverse events of any intensity (whether drug-related or not) occurring in 2% or more of the patients in either treatment group in the combined analysis, along with point estimates and 95% confidence intervals for the difference between the two treatment groups for each organ system. Adverse event terms are from the Medical Dictionary for Regulatory Activities (MedDRA), version 10.1. Table A4 in Supplementary Appendix 2 lists all laboratory abnormalities of grade 2, 3, or 4, according to the Division of AIDS (DAIDS) criteria (http://rcc.tech-res-intl.com/tox_tables.htm), occurring in patients in the combined BENCHMRK studies. LDL denotes low-density lipoprotein, and ULN upper limit of the normal range.

† The clinical adverse events listed are those present in 2% or more of patients in either treatment group and determined by an investigator to be possibly, probably, or definitely related to the use of a study drug. Reaction at injection site and pain at injection site were considered to be attributable to enfuvirtide injection.

🕆 The laboratory-abnormality grade was assigned on the basis of the DAIDS criteria. Except for creatine kinase, the laboratory test results reported in the table were specified to be graded before the data were unblinded.

🖇 Data on fasting LDL cholesterol were available for 218 patients in each raltegravir group and 109 patients in each placebo group.

phoma, shock and multiorgan failure; coronary artery disease; cardiorespiratory arrest; non-Hodgkin's lymphoma; hepatocellular carcinoma; esophageal candidiasis; the wasting syndrome; and mixed infection with tuberculosis and aspergillosis. In the placebo groups, the fatal adverse events were pneumonia; urosepsis; worsening of end-stage AIDS; AIDS dementia complex; failure to thrive, dehydration, and respiratory failure; and sepsis.

As of the cutoff dates for this analysis, 16 of 462 raltegravir recipients (3.5%) and 4 of 237 placebo recipients (1.7%) had been given a diagnosis of new, recurrent, or progressive cancer during the double-blind phases of the two studies (Table 5). All cancers were reported as serious adverse events not related to a study drug, except for lymphoma in one placebo recipient that was considered to be possibly drug related. With adjustment for person-years of follow-up during the double-blind phases of the two studies, the relative risk of cancer in the raltegravir groups as compared with the placebo groups was 1.54 (95% CI, 0.50 to 6.34). The median time during the study when cancer was diagnosed

was 68 days (interquartile range, 30 to 118) among raltegravir recipients and 285 days (interquartile range, 246 to 336) among placebo recipients. Except for two raltegravir recipients, by the time of the cancer diagnosis, patients had had a response to the study therapy: an increase in the CD4 cell count by 50 or more per cubic millimeter, a decrease in the HIV-1 RNA level by 1 log₁₀ copies per milliliter or more, or an HIV-1 RNA level of less than 400 copies per milliliter. In three raltegravir recipients, immune reconstitution was considered by the investigators to have possibly contributed to the diagnosis of cancer. Five of the patients with cancer in the raltegravir group had died by the cutoff dates for this analysis.

DISCUSSION

Highly active antiretroviral therapy effectively suppresses viremia in most patients with advanced HIV infection who comply with their antiretroviral regimen, but drug-resistant virus emerges in some patients.^{12-14,20,32-34} In addition, transmission of resistant HIV places patients

Type of Cancer	Raltegravir G	Placebo Groups (N=237)					
	New	Relapse	New	Relapse			
		no. of p	of patients				
Any	10	6	3	1			
Kaposi's sarcoma	1	1	0	0			
Non-Hodgkin's lymphoma							
B cell	1	1	0	0			
T cell	1	0	0	0			
Unspecified	0	0	1	0			
Anal squamous-cell carcinoma							
Invasive	2	0	2	0			
In situ carcinoma	1	2	0	0			
Rectal adenocarcinoma	1	0	0	0			
Hepatocellular carcinoma	1	0	0	0			
Skin cancer							
Basal-cell carcinoma	0	1	0	1			
Squamous-cell carcinoma	2	1	0	0			
Laryngeal squamous-cell carcinoma	1	0	0	0			

* One patient in the raltegravir group was given a diagnosis of both Kaposi's sarcoma and anal carcinoma. Relapses included recurrent or progressive cancers initially diagnosed before study entry. who have not previously received treatment at risk for suboptimal responses to first-line regimens.^{10,15-18,35,36} Historically, as compared with the initial regimens, subsequent antiretroviral regimens used in patients with resistant virus after treatment failures have been much less successful in suppressing viremia.^{1,12,20,21,32,33,37,38} Raltegravir inhibits HIV-1 replication through a mechanism of action distinct from that of other currently approved antiretroviral drugs and thus offers the promise of potent activity against multidrug-resistant virus.^{26-28,31}

In patients infected with HIV that had tripleclass drug resistance, raltegravir given at a dose of 400 mg twice daily at intervals of 12 (±2) hours, with optimized background therapy, had a rapid and potent antiretroviral effect that was superior to the effect of optimized background therapy alone at week 48. These results were consistent between the two BENCHMRK studies. The majority of patients in both studies had AIDS at entry and had failure of multiple previous antiretroviral regimens, with the emergence of highly resistant virus. The inferior virologic responses in the placebo groups as compared with the raltegravir groups were consistent with the findings in other studies targeting similar populations and attest to the shortcomings of older treatment options in this context.39-47 Immunologic benefits evidenced by increased CD4 cell counts were also observed during raltegravir therapy.

Overall, adverse-event profiles were generally similar for the raltegravir and placebo regimens. The disproportionate diagnosis of several cancers in the raltegravir groups as compared with the placebo groups at the time of the 16-week analyses in the two BENCHMRK studies prompted a comprehensive review of all cancers occurring in the four phase 2-3 trials of raltegravir.31,48,49 Data from three studies of heavily pretreated patients were combined with data from one study of previously untreated patients and were adjusted for the duration of follow-up during the double-blind phases.50 The relative risk of cancer associated with raltegravir, as compared with placebo, was 1.2 (95% CI, 0.4 to 4.1) in the most current analysis, with a composite rate of 2.2 cancers per 100 patient-years in the raltegravir groups (vs. 1.8 per 100 patient-years in the placebo groups). The types and frequencies of cancers were similar to those reported in patients with advanced HIV infection.⁵¹ Most patients with a diagnosis of cancer had favorable virologic and immunologic responses. Cancers were generally detected earlier after the initiation of study therapy in the raltegravir groups than in the placebo groups. Although usually associated with AIDS-related opportunistic infections, the immune reconstitution syndrome has been linked to the detection of cancer.⁵²⁻⁶² No evidence of carcinogenicity was apparent from the preclinical data on raltegravir. Continued vigilance in the monitoring of safety is nonetheless warranted.

Our results should be interpreted in the context of the prelicensure experience with this new class of drugs in a limited number of patients to date.31,48,49 Data on the efficacy, safety, and tolerability of raltegravir given for 48 or more weeks are accumulating.49,63 The durability of viral suppression and the tolerability of longerterm therapy with raltegravir-based combination regimens continue to be assessed in the ongoing BENCHMRK studies. The development of resistance to integrase inhibitors is a particular concern when raltegravir is by necessity used as functional monotherapy (in which there are no fully active drugs in the optimized background therapy).^{12,20,48,64,65} Although viral suppression has been found in some patients whose optimized background therapy had a genotypic or phenotypic sensitivity score of 0, some drugs used in the optimized background therapy may have retained partial antiretroviral activity.48 In contrast, baseline resistance testing may have failed to detect archived resistance mutations present at frequencies below the limit of detection of the assay, thereby possibly inflating some sensitivity scores in both treatment groups.

In patients with few remaining treatment options, raltegravir combined with optimized background therapy provided superior HIV-1 suppression as compared with optimized background therapy alone, despite the presence of virus that has triple-class drug resistance. The potent suppression of viremia seen at week 16 in raltegravir recipients was usually achieved by week 4 and sustained through week 48. As with other new antiretroviral agents under development that work through novel mechanisms of action,⁶⁶ raltegravir as part of an optimized combination regimen offers hope for the suppression of HIV-1 infection that is resistant to standard therapies.^{67,68} Supported by Merck.

Dr. Steigbigel reports serving as an investigator for Merck, Pfizer, and Boehringer Ingelheim; Dr. Cooper, serving as an investigator for and receiving speaker's and advisory fees from Merck; Dr. Kumar, serving as an investigator for and receiving consulting and lecture fees from Merck; Dr. Eron, serving as an investigator for Merck, GlaxoSmithKline, Abbott, and Panacos and receiving consulting or lecture fees from Merck, Gilead, Bristol-Myers Squibb, GlaxoSmithKline, Abbott, Trimeris, Roche, Virco, Monogram, and Panacos; Dr. Schechter, serving as an investigator for Merck and receiving consulting fees or lecture fees from Merck, Gilead, Bristol-Myers Squibb, Abbott, Roche, and Pfizer; Dr. Markowitz, serving as an investigator for Merck, GlaxoSmithKline, Gilead, and Tibotec and receiving consulting fees from Merck, Gilead, GlaxoSmithKline, Sequoia Pharmaceuticals, and Quintiles and grant support from Merck and Pfizer; Dr. Loutfy, serving as an investigator for Merck; Dr. Lennox, serving as an investigator for Merck, Gilead, Pfizer, Tibotec, Schering, and Abbott and receiving consulting fees from Merck, Roche, and Abbott; Dr. Gatell, receiving grant support or lecture or advisory fees from Merck, Roche, GlaxoSmithKline, Bristol-Myers Squibb, Tibotec, Pfizer, Gilead, Abbott, and Boehringer Ingelheim; Dr. Rockstroh, receiving lecture or advisory fees from Merck, Roche, GlaxoSmithKline, Bristol-Myers Squibb, Tibotec, Pfizer, Gilead, Abbott, and Boehringer Ingelheim; Dr. Katlama, receiving advisory or lecture fees from Merck, Gilead, Roche, GlaxoSmithKline, Tibotec, Bristol-Myers Squibb, and Boehringer Ingelheim; Dr. Yeni, receiving grant support and advisory fees from Tibotec, Merck, GlaxoSmithKline, Pfizer, Gilead, Abbott, and Boehringer Ingelheim; Dr. Lazzarin, receiving advisory fees from Merck and consulting and lecture fees from Gilead, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Tibotec, Boehringer Ingelheim, Pfizer, Merck, and Abbott; Dr. Clotet, receiving consulting and lecture fees from Gilead, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Tibotec, Boehringer Ingelheim, Pfizer, Merck, and Abbott; and Drs. Zhao, Chen, Meibohm, Miller, Hazuda, DiNubile, Isaacs, Nguyen, and Teppler, Mr. Ryan, Mr. Rhodes, Mr. Killar, Ms. Gilde, Ms. Strohmaier, and Mr. Nessly, being employees of Merck and owning stock or stock options or both in the company. No other potential conflict of interest relevant to this article was reported.

We thank all the patients and their caregivers who participated in the BENCHMRK studies; the investigators who enrolled their patients in these trials for their important contributions; Keith Gottesdiener for his thoughtful advice; and Joann DiLullo, Karyn Davis, Anita Jain, Andrea Karian, Hong Wan, Jennifer Reinert, Bernard Akyena, Xia Xu, and Anthony Rodgers for their expert assistance.

REFERENCES

1. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-43.

2. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001;344:824-31.

3. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999;13:963-9.

4. Hornberger J, Kilby JM, Wintfeld N, Green J. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. AIDS Res Hum Retroviruses 2006;22:240-7.

5. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viralload reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.

6. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.

7. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.

8. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999;179:717-20.

9. Barreto CC, Nishyia A, Araújo LV, Ferreira JE, Busch MP, Sabino EC. Trends in antiretroviral drug resistance and clade distributions among HIV-1–infected blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr 2006;41:338-41.

10. Gentz M, Levin TP, Klibanov OM, Feingold A, Condoluci DV. Three-class antiretroviral resistance in a patient with acute HIV-1 infection. AIDS Patient Care STDS 2006;20:741-4.

11. Kijak GH, Pampuro SE, Avila MM, et al. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antivir Ther 2001;6:71-7.

12. Kolber MA, Campo RE, Dickinson GM. Development of anti-retroviral resistance of HIV-1 infected individuals on therapy: is it inevitable? IUBMB Life 2004; 56:301-7.

13. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-401.

14. Tozzi V, Zaccarelli M, Bonfigli S, et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther 2006;11:553-60.
15. Truong HM, Grant RM, McFarland W, et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 2006;20:2193-7.

16. Turner D, Wainberg MA. HIV transmission and primary drug resistance. AIDS Rev 2006;8:17-23.

17. Van Laethem K, De Munter P, Schrooten Y, et al. No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol 2007;39:43-7.

18. Viani RM, Peralta L, Aldrovandi G, et al. Prevalence of primary HIV-1 drug re-

sistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis 2006:194:1505-9.

19. Ross L, Liao Q, Gao H, et al. Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy. AIDS Res Hum Retroviruses 2001;17:1379-85.

20. Temesgen Z, Cainelli F, Poeschla EM, Vlahakis SA, Vento S. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis 2006;6:496-507.

21. de Béthune MP, Hertogs K. Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance. Curr Med Res Opin 2006;22: 2603-12.

 De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs 2005;10:241-73.
 Gulick RM. New antiretroviral drugs. Clin Microbiol Infect 2003;9:186-93.

24. Torti C, Quiros-Roldan E, Regazzi M, et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentrationcontrolled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin Infect Dis 2005:40:1828-36.

25. Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs 2006;15:1507-22.

26. Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A 2000; 97:11244-9. **27.** Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50.

28. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004;305:528-32.

29. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007;35:1657-63.

30. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-15. [Erratum, J Acquir Immune Defic Syndr 2007;44:492.]

31. Grinsztejn B, Nguyen B-Y, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369:1261-9.

32. Karmochkine M, Si Mohamed A, Piketty C, et al. The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients. Antiviral Res 2000;47:179-88.

33. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy: Swiss HIV Cohort Study. AIDS 1999;13: F17-F21.

34. Machouf N, Thomas R, Nguyen VK, et al. Effects of drug resistance on viral load in patients failing antiretroviral therapy. J Med Virol 2006;78:608-13.

35. Bezemer D, de Ronde A, Prins M, et al. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther 2006; 11:173-7.

36. Welles SL, Bauer GR, LaRussa PS, Colgrove RC, Pitt J. Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and naive pregnant women in New York City during 1991 to early 2001. J Acquir Immune Defic Syndr 2007;44:329-35.

37. Luber AD. Treatment strategies for highly treatment-experienced HIV-infected patients. Expert Rev Anti Infect Ther 2005;3:815-23.

38. Vallejo A, Olivera M, Rubio A, Sánchez-Quijano A, Lissen E, Leal M. Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen. Antiviral Res 2004;61:129-32. **39.** Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370: 29-38.

40. Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43:1347-56.

41. Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006;43: 1337-46.

42. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised openlabel trials. Lancet 2006;368:466-75.

43. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348: 2175-85. [Erratum, N Engl J Med 2003; 349:1100.]

44. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95.
45. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402.

46. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatmentexperienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007;46:24-31.

47. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370: 39-48.

48. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-65.

49. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 in-

fection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-33.

50. Raltegravir NDA 22-145. (Accessed June 30, 2008, at http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4314s1-06-connelly_files/slide0089.htm.)

51. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67.

52. Arici C, Ripamonti D, Ravasio V, et al. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution. Int J STD AIDS 2001;12:573-81.

53. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38:1159-66.

54. Hoffmann C, Horst HA, Weichenthal M, Hauschild A. Malignant melanoma and HIV infection — aggressive course despite immune reconstitution. Onkologie 2005;28:35-7.

55. Knysz B, Kuliszkiewicz-Janus M, Jelen M, Podlasin R, Gladysz A. Non-Hodgkin's lymphoma as a rare manifestation of immune reconstitution disease in HIV-1 positive patients. Postepy Hig Med Dosw (Online) 2006;60:547-51.

56. Knysz B, Zalewska M, Rzeszutko M, Gladysz A. Lung cancer as an immune reconstitution disease in an HIV-1 positive man receiving HAART. Postepy Hig Med Dosw (Online) 2006;60:181-3.

57. Powles T, Thirlwell C, Nelson M, Bower M. Immune reconstitution inflammatory syndrome mimicking relapse of AIDS related lymphoma in patients with HIV 1 infection. Leuk Lymphoma 2003;44: 1417-9.

58. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418-27.

59. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006;42:1639-46.

60. Robertson P, Scadden DT. Immune reconstitution in HIV infection and its relationship to cancer. Hematol Oncol Clin North Am 2003;17:703-16.

61. Venkataramana A, Pardo CA, McArthur JC, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006;67:383-8.
62. Mermet I, Guerrini JS, Cairey-Remonnay S, et al. Cervical intraepithelial neoplasia associated with epidermodysplasia verruciformis HPV in an HIV-infected pa-

tient: a manifestation of immune restoration syndrome. Eur J Dermatol 2007;17: 149-52.

63. Grinsztejn B, Nguyen B, Katlama C, et al. 48 Week efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 17–20, 2007. abstract.

64. Youle M, Staszweski S, Clotet B, et al. Concomitant use of an active boosted

protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. HIV Clin Trials 2006;7: 86-96.

65. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007; 60:885-8.

66. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of

vicriviroc, a CCR5 inhibitor, in HIV-1infected treatment-experienced patients. J Infect Dis 2007;196:304-12.

67. Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr. Tripleclass antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS 2007;21:825-34.

68. Cahn P, Sued O. Raltegravir: a new antiretroviral class for salvage therapy. Lancet 2007;369:1235-6.